动脉粥样硬化性血管疾病是人类生命健康的头号杀手，其发病机制复杂，单基因、通路、药物的应用效果尚不够显著，且常规药物缺乏靶向性和诊断功能。本研究在课题组前期合成的聚乙烯亚胺-环糊精基础上，通过主客体组装技术将疏水药物中性白细胞弹性蛋白酶抑制剂GW311616A插入到环糊精的空腔中，载体运载 CD146-siRNA-FITC后形成纳米粒；然后通过VCAM-1特异性配体修饰的红细胞膜包裹纳米粒，最终形成具有红细胞膜包裹（R）、动脉粥样斑块靶向性（O）、分子成像（M）、多重药理功效（M）的ROMM纳米材料。ROMM将通过靶向输送、荧光成像、控制释放，定点高效地作用于动脉粥样斑块，并发挥载体本身、药物、基因的三重协同治疗效果。研究将从体内/体外实验明确ROMM的形态结构、药代动力学、靶向性以及生物学效应，阐明其在治疗过程中的多重机制。本研究将为纳米材料用于动脉粥样硬化疾病精准诊疗一体化提供新的思路。

Atherosclerotic vascular disease is the first killer of human life and health while its pathogenesis is complex. Application of single gene, pathway, or drug is not effective yet. What’s more, conventional drugs are short of targeting and diagnostic function. On the basis of the polyethylenimine-cyclodextrin (PEI-CyD) nanomaterials synthesized in our previous research, PEI-CyD is self-assembled with the hydrophobic drug neutrophil elastase inhibitor (GW311616A) via host-guest interaction, carried with FITC labeled CD146-siRNA and encapsulated by VCAM-1-specific ligand-modified red blood cell membrane, eventually forming a Red blood cell membrane encapsulated (R), Oligopeptide-guided (O), Molecular imaging , Multiple pharmacological effects (M) multifunctional delivery system (ROMM). ROMM system will produce triple synergistic efficacy with the carrier itself, therapeutic drug and functional gene in atherosclerotic plaque via targeted delivery, fluorescence imaging and controlled release. Our study will illustrate the morphological structure, pharmacokinetics, targeting and biological effects of ROMM and elucidate the multiple mechanisms of ROMM by in vivo / in vitro experiments. This study will provide new insights for the precision diagnosis and treatment of atherosclerotic diseases by nanomaterials.